Det vides ikke, om denne leukæmogene effekt er sekundær til hydroxycarbamid eller forbundet med patientens bagvedliggende sygdom.
It is unknown whether this leukemogenic effect is secondary to hydroxycarbamide or is associated with the patient’ s underlying disease.